by Market Overview:
Bacterial sialadenitis refers to an infection of one or more salivary glands caused by bacteria. It leads to swelling and pain in salivary glands located below the ears and around the jawline. The prominent symptoms include soreness or tenderness of the gland, swelling of one or more glands, and fever. It is usually treated with oral antibiotics such as penicillin, cephalosporins, and clindamycin. Some of the major causes of bacterial sialadenitis include streptococcus, staphylococcus, tuberculosis, and infections related to HIV/AIDS.
Market Dynamics:
The increasing prevalence of bacterial infections is expected to drive the growth of the bacterial sialadenitis market over the forecast period. For instance, according to the National Institute of Dental and Craniofacial Research, it is estimated that by 2030, the global prevalence of oral diseases will reach 4.2 billion people. Oral infections and related diseases are one of the major causes of bacterial sialadenitis.
Growing geriatric population is also expected to aid in growth of the market. Aged people are more prone to infections such as bacterial sialadenitis as their immunity decreases with age. According to the United Nations Department of Economic and Social Affairs, in 2030, there will be around 1.4 billion people aged 60 years and older globally.
The global Bacterial Sialadenitis Market Share is estimated to be valued at US$ 1.90 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global bacterial sialadenitis market can be segmented on the basis of type, treatment, end user and distribution channel. Based on type, the market is segmented as acute bacterial sialadenitis and chronic bacterial sialadenitis. The chronic bacterial sialadenitis dominates the market as it has high prevalence rate as compared to the acute type. Based on treatment, the market is segmented as antibiotics, pain medications, surgery and others. The antibiotics segment dominates the market as it is the first line of treatment for both acute and chronic bacterial sialadenitis.
PEST Analysis
Political: The regulations related to the approval of drugs and medical devices by regulatory authorities like FDA are expected to impact the bacterial sialadenitis market.
Economic: Rising geriatric population suffering from chronic diseases and improved healthcare expenditure is expected to drive the market growth during the forecast period.
Social: Increasing awareness about treatment options and various campaigns by medical associations are raising awareness about bacterial sialadenitis.
Technological: The adoption of advanced techniques like endoscopic sialoadenectomy and minimally invasive sialendoscopy for diagnosis and treatment are providing new avenues for market growth.
Key Takeaways
The global bacterial sialadenitis market size is expected to reach US$ 2.01 Bn by 2023, exhibiting a CAGR of 5.6% during the forecast period due to increasing prevalence of chronic diseases and growing geriatric population. North America is expected to dominate the market during the forecast period owing to rising healthcare expenditure and presence of major market players in the region. Key players operating in the bacterial sialadenitis market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Allergan plc.
Regional analysis
North America is expected to hold the largest share in the global bacterial sialadenitis market during the forecast period. This is mainly attributed to the rising prevalence of chronic diseases, increasing geriatric population, technological advancements and growing healthcare expenditure in the region. Asia Pacific market is projected to exhibit the highest growth rate during the forecast period owing to increasing patient awareness about the disease, improving healthcare infrastructure and rising healthcare expenditure in emerging countries like India and China.
Key players
Key players operating in the bacterial sialadenitis market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Allergan plc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
